{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:07:11Z","timestamp":1790755631693,"version":"4.1.0"},"reference-count":63,"publisher":"American Society for Clinical Investigation","issue":"15","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01HL128237"],"award-info":[{"award-number":["R01HL128237"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000901","name":"Juvenile Diabetes Research Foundation International","doi-asserted-by":"crossref","award":["3-PDF2014-188-A-N"],"award-info":[{"award-number":["3-PDF2014-188-A-N"]}],"id":[{"id":"10.13039\/100000901","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8,9]]},"abstract":"<jats:p>Despite advances in antithrombotic therapy, the risk of recurrent coronary\/cerebrovascular ischemia or venous thromboembolism remains high. Dual pathway antithrombotic blockade, using both antiplatelet and anticoagulant therapy, offers the promise of improved thrombotic protection; however, widespread adoption remains tempered by substantial risk of major bleeding. Here, we report a dual pathway therapeutic capable of site-specific targeting to activated platelets and therapeutic enrichment at the site of thrombus growth to allow reduced dosing without compromised antithrombotic efficacy. We engineered a recombinant fusion protein, SCE5-TAP, which consists of a single-chain antibody (SCE5) that targets and blocks the activated GPIIb\/IIIa complex, and tick anticoagulant peptide (TAP), a potent direct inhibitor of activated factor X (FXa). SCE5-TAP demonstrated selective platelet targeting and inhibition of thrombosis in murine models of both carotid artery and inferior vena cava thrombosis, without a significant impact on hemostasis. Selective targeting to activated platelets provides an attractive strategy to achieve high antithrombotic efficacy with reduced risk of bleeding complications.<\/jats:p>","DOI":"10.1172\/jci.insight.99329","type":"journal-article","created":{"date-parts":[[2018,8,8]],"date-time":"2018-08-08T11:01:03Z","timestamp":1533726063000},"source":"Crossref","is-referenced-by-count":31,"title":["Platelet-targeted dual pathway antithrombotic inhibits thrombosis with preserved hemostasis"],"prefix":"10.1172","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5403-544X","authenticated-orcid":true,"given":"Donny","family":"Hanjaya-Putra","sequence":"first","affiliation":[{"name":"Department of Surgery, Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School, Boston, Massachusetts, USA."},{"name":"Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Haller","sequence":"additional","affiliation":[{"name":"Department of Surgery, Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School, Boston, Massachusetts, USA."},{"name":"Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Wang","sequence":"additional","affiliation":[{"name":"Baker Heart and Diabetes Research Institute, Melbourne, VIC 8008, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erbin","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Surgery, Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School, Boston, Massachusetts, USA."},{"name":"Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bock","family":"Lim","sequence":"additional","affiliation":[{"name":"Baker Heart and Diabetes Research Institute, Melbourne, VIC 8008, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Surgery, Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Jaminet","sequence":"additional","affiliation":[{"name":"University Hospital, Freiburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Yao","sequence":"additional","affiliation":[{"name":"Baker Heart and Diabetes Research Institute, Melbourne, VIC 8008, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Searle","sequence":"additional","affiliation":[{"name":"Baker Heart and Diabetes Research Institute, Melbourne, VIC 8008, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0412-8223","authenticated-orcid":true,"given":"Thomas","family":"Bonnard","sequence":"additional","affiliation":[{"name":"Baker Heart and Diabetes Research Institute, Melbourne, VIC 8008, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph E.","family":"Hagemeyer","sequence":"additional","affiliation":[{"name":"Baker Heart and Diabetes Research Institute, Melbourne, VIC 8008, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karlheinz","family":"Peter","sequence":"additional","affiliation":[{"name":"Baker Heart and Diabetes Research Institute, Melbourne, VIC 8008, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliot L.","family":"Chaikof","sequence":"additional","affiliation":[{"name":"Department of Surgery, Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School, Boston, Massachusetts, USA."},{"name":"Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, Massachusetts, USA."},{"name":"Harvard-MIT Division of Health Sciences and Technology, Cambridge, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"232","published-online":{"date-parts":[[2018,8,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05701-4"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904327"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105819"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.115386"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.05.029"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61751-7"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.002927"},{"issue":"2","key":"B11","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002587","article-title":"Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI48 Trial","volume":"5","author":"Xu","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2014.156"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht445"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.11.013"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.5398"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2016.05.039"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.113.001150"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1955"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-011551"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-12-0771"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000232317.84122.0c"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-449694"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)62177-1"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112277"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1177\/1074248415578172"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109719"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2017.206"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1126\/science.2333510"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2004.07.009"},{"issue":"9 Suppl 1","key":"B30","first-page":"I3","article-title":"Initial treatment of venous thromboembolism","volume":"110","author":"McRae","year":"2004","journal-title":"Circulation"},{"issue":"Suppl 1","key":"B31","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s00772-016-0227-6","article-title":"Mouse models of deep vein thrombosis","volume":"22","author":"Sch\u00f6nfelder","year":"2017","journal-title":"Gefasschirurgie"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.111.244608"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1160\/TH12-09-0711"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/anie.201408529"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.030312"},{"issue":"9","key":"B36","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1182\/blood.V88.9.3432.bloodjournal8893432","article-title":"Blood clotting in minimally altered whole blood","volume":"88","author":"Rand","year":"1996","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.106.138875"},{"issue":"1","key":"B38","first-page":"47","article-title":"Fibrin-targeted direct factor Xa inhibition: construction and characterization of a recombinant factor Xa inhibitor composed of an anti-fibrin single-chain antibody and tick anticoagulant peptide","volume":"92","author":"Hagemeyer","year":"2004","journal-title":"Thromb Haemost"},{"key":"B39","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1538-7836.2007.02473.x","article-title":"Factor Xa or thrombin: is factor Xa a better target?","volume":"5 Suppl 1","author":"Ansell","year":"2007","journal-title":"J Thromb Haemost"},{"key":"B40","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1538-7836.2007.02552.x","article-title":"Factor Xa or thrombin: is thrombin a better target?","volume":"5 Suppl 1","author":"Weitz","year":"2007","journal-title":"J Thromb Haemost"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/nbt846"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-398149"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-261610"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201200607"},{"key":"B45","article-title":"Engineering Factor Xa Inhibitor with Multiple Platelet-Binding Sites Facilitates its Platelet Targeting","volume":"6","author":"Zhu","year":"2016","journal-title":"Sci Rep"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2011.08.067"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1172\/JCI81470"},{"issue":"8","key":"B48","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.005991","article-title":"ADPase CD39 Fused to Glycoprotein VI-Fc Boosts Local Antithrombotic Effects at Vascular Lesions","volume":"6","author":"Degen","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1021\/jm400236j"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006804"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405760"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-06-163675"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050664"},{"issue":"8171","key":"B54","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(80)91275-1","article-title":"Hageman factor deficiency and oral contraceptives","volume":"1","author":"Mangal","year":"1980","journal-title":"Lancet"},{"key":"B55","article-title":"A Novel Direct Factor Xa Inhibitory Peptide with Anti-Platelet Aggregation Activity from Agkistrodon acutus Venom Hydrolysates","volume":"5","author":"Chen","year":"2015","journal-title":"Sci Rep"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-08330-1"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1006\/prep.2000.1258"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.114.302514"},{"issue":"53","key":"B59","doi-asserted-by":"crossref","DOI":"10.3791\/2737","article-title":"Electrolytic inferior vena cava model (EIM) of venous thrombosis","author":"Diaz","year":"2011","journal-title":"J Vis Exp"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.5493\/wjem.v2.i2.30"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1084\/jem.181.2.669"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1084\/jem.190.12.1769"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/nm782"}],"container-title":["JCI Insight"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/insight.jci.org\/articles\/view\/99329\/files\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:57:29Z","timestamp":1779195449000},"score":1,"resource":{"primary":{"URL":"https:\/\/insight.jci.org\/articles\/view\/99329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,9]]},"references-count":63,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2018,8,9]]},"published-print":{"date-parts":[[2018,8,9]]}},"alternative-id":["10.1172\/jci.insight.99329"],"URL":"https:\/\/doi.org\/10.1172\/jci.insight.99329","relation":{},"ISSN":["2379-3708"],"issn-type":[{"value":"2379-3708","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,9]]},"article-number":"e99329"}}